The data by Drs Shingu and Matsui suggest the utility and need for procedures to address subvalvular tethering in patients with ischemic MR. Currently reported surgical procedures to address subvalvular tethering are conceptually reasonable and heterogenous. [3] [4] [5] A tailored and heterogeneous approach based on preoperative 3-dimensional evaluation of mitral valve geometry seems necessary to address patients' variability. Standardization is also necessary to perform subvalvular procedures in many institutions. This bidirectional improvement in therapeutic approach is required to achieve a favorable outcome in affected patients. 
reperfusion injury in rats. In this study, cyclophosphamide showed a favorable effect on myocardial function in various parameters, which included improvement in left ventricular systolic pressure, left ventricular end-diastolic pressure, and maximum rate of rise or fall of left ventricular pressure. Apart from this, infarct size was reduced, along with improvement in histopathologic damage score, and plasma highsensitivity C-reactive protein concentration, which is an inflammatory marker, was reduced significantly. However, we would like to highlight some of the points regarding this study 1. The study showed that cyclophosphamide decreased the C-reactive protein levels significantly, but it is not the proposed specific mechanism of action alone to have anti-inflammatory action. Other markers of inflammation, such as Cox inhibition, should also have been evaluated before making the final conclusion. 2. In this study, pretreatment with cyclophosphamide or saline was given before inducing ischemia/reperfusion. Thus, in this study design, investigators should have evaluated whether the drug cyclophosphamide or saline had any beneficial or detrimental effect before proceeding for ischemia and reperfusion or sham surgery. 3. The cardioprotective role of cyclophosphamide could have been evaluated on creatine kinase, myocardial band of creatine kinase, and tropinin I, which are the myocardial injury markers. 2, 3 4. Various studies have evaluated the role of cytokines, which include interleukins 6 and 8, interferongamma, and tumor necrosis factora, which are upregulated after ischemia/reperfusion injury. 4, 5 In this present study, too, the expression of these cytokines, which are mediators of inflammation, could have been evaluated in comparison with saline or cyclophosphamide. The present study provides useful information for more effective and targeted treatment for patients with ischemic heart disease, but the aforementioned points should be discussed for future therapeutic implication and reconfirmation in clinical studies.
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